Objective

Surgical site infection is the most detrimental complication following cranioplasty. In other surgical fields, intrawound vancomycin powder application has been introduced to prevent surgical site infection and is widely used based on results in multiple studies. This study evaluated the effect of intrawound vancomycin powder in cranioplasty compared with the conventional method without topical antibiotics.

Methods

This retrospective study included 580 patients with skull defects who underwent cranioplasty between August 1, 1998 and December 31, 2021. The conventional method was used in 475 (81.9%; conventional group) and vancomycin powder (1g) was applied on the dura mater and bone flap in 105 (18.1%; vancomycin powder group) patients. Surgical site infection was defined as infection of the incision, organ, or space that occurred after cranioplasty. Surgical site infection within one-year surveillance period was compared between the conventional and vancomycin powder groups with logistic regression analysis. Penalized likelihood estimation method was used in logistic regression to deal with zero events. All local and systemic adverse events associated with topical vancomycin application were also evaluated.

Results

Surgical site infection occurred in 31 (5.3%) patients and all were observed in the conventional group. The median time between cranioplasty and detection of surgical site infection was 13 days (range, 4 - 333). Staphylococci were the most common organisms and identified in 25 (80.6%) of 31 cases with surgical site infections. The surgical site infection rate in the vancomycin powder group (0/105 [0%]) was significantly lower than that in the conventional group (31/475 [6.5%]; crude odds ratio 0.067 [95% confidence interval 0.006 - 0.762], adjusted odds ratio 0.068 [95% confidence interval 0.006 - 0.731]; p=0.026). No adverse events associated with intrawound vancomycin powder were observed during the follow-up.

Conclusions

Intrawound vancomycin powder effectively prevented surgical site infections following cranioplasty without local or systemic adverse events. Our results suggest that intrawound vancomycin powder is an effective and safe strategy for patients undergoing cranioplasty.


PMID 37032483